Healthy Delights expands offering through GNC
WEST PALM BEACH, Fla. — Healthy Delights on Monday launched five new products in GNC stores nationwide, including Probiotic Chocolate Bites, Probiotic Greek Yogurt Bites, Turmeric Curcumin Chews, Magnesium Chews and Cranberry Chews. The new offerings will generate significant growth for Healthy Delights and will further position the brand as the go-to soft chew supplement to stay healthy, the company stated.
"Healthy Delights was developed with the goal of delivering high-quality supplements and nutritional snacks in a delicious and convenient way," stated Al Baumeler, SVP marketing. "We are thrilled to expand our brand in GNC and give health-conscious consumers an enjoyable new way to keep their families – and themselves – healthy."
GNC will offer the full selection of nutritious and delicious Healthy Delights supplements starting May 18, 2015. The fully branded in-store display will offer customers a free sample of the different supplements available.
Care teams including pharmacists better manage high blood pressure
IOWA CITY, Iowa — If you have hypertension, it pays to include a pharmacist in a medical-care team.
That's the upshot from research by the University of Iowa that found patients with uncontrolled hypertension had better blood-pressure control when being cared for by pharmacists working in care teams (with a physician, for example), than patients who relied mostly on a doctor for medication guidance.
The researchers showed pharmacist-included care teams delivered more hands-on and tailored medication regimens to patients, which yielded more effective blood-pressure control results than for those patients who did not have a pharmacist on hand.
UI pharmacy research associate Tyler Gums will present the findings Monday at the American Society of Hypertension annual conference in New York.
The results come from two studies done by research teams led by Barry Carter, UI pharmacy professor.
For the study, UI researchers enrolled 625 patients from various racial backgrounds with uncontrolled hypertension from 32 medical offices across 15 states in the United States. They then evaluated how well patients were able to control their blood pressure when getting care from a medical team that included a pharmacist compared to being treated by a physician only. The study took place between March 2010 and June 2013.
The researchers measured patients' blood pressure control, the degree and intensity of care they received and how well they followed medication recommendations.
The UI team found that patients who saw a medical team that included a clinical pharmacist showed a systolic blood pressure drop of 6.1 mmHg nine months later compared to those who did not see a clinical pharmacist during the same time. A reduction of that scale would reduce the chances of death by stroke by 23%, the researchers noted. "That means, if you saw a care team with a clinical pharmacist, your blood pressure was more likely to be lower," said Gums, a postdoctoral researcher in the UI College of Pharmacy.
Moreover, patients in the pharmacist-included care teams had their medications adjusted an average of 4.9 times during the nine-month period, of which three instances involved dose increases or added medications, according to the study.
Patients who saw physicians only averaged one adjusted medication and less than one instance of dose increases or added medications in the same period, the researchers found.
"Clinical pharmacists were able to contribute to the care team by tailoring blood pressure medications for each patient and spent extra time educating patients on how to decrease their blood pressure," Gums explained.
The researchers found patients in the pharmacist-included care teams did not follow their medication recommendations more readily than the control group. Further research is needed to understand why.
The National Institutes of Health funded the work.
Nascent market for connected wearable patches holds great promise
BOULDER, Colo. — According to a new report from Tractica released Monday, worldwide unit shipments of clinical and non-clinical connected wearable patches (not wearable devices) will grow to 12.3 million annually by 2020, up from just 67,000 in 2014. During that period, the market intelligence firm forecasts that the market for such patches will increase to $3.3 billion annually.
“The nascent market for connected wearable patches holds great promise, with the potential to improve the health of patients and contribute to lower healthcare costs,” stated principal analyst Charul Vyas. “It is, however, still very much in the early stages of development and commercial availability. Connected wearable patches face a variety of challenges that must be overcome in the next several years in order for the market to thrive.”
Connected wearable patches include patches, tattoos, or small devices that are affixed to the skin and worn for a limited period of time, ranging from an hour to several weeks. The patches also have an element of wireless connectivity, and have a medical, health or wellness purpose that can range from monitoring physiological data to delivering medication.
Driven by rising healthcare costs, a growth in the number of people with chronic diseases and aging populations, connected wearable patches are becoming an attractive solution for governments, insurance companies and care providers, all of whom are searching for more cost-effective ways to monitor, diagnose and treat patients.
Loading Post Please Wait...